The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Abstract Text:

H Fallah Huseini,B Larijani,R Heshmat,H Fakhrzadeh,B Radjabipour,T Toliat,Mohsin Raza,

Oxidative stresses are increasingly implicated in the pathogenesis of diabetic complications which may either cause direct pancreatic beta-cell damage or lead to metabolic abnormalities that can induce or aggravate diabetes. The valuable effect of antioxidant nutrients on the glycemic control of diabetic patients has been reported in experimental and clinical studies. The present study was designed to investigate the effects of the herbal medicine, Silybum marianum seed extract (silymarin), which is known to have antioxidant properties on the glycemic profile in diabetic patients. A 4-month randomized double-blind clinical trial was conducted in 51 type II diabetic patients in two well-matched groups. The first group (n = 25) received a silymarin (200 mg) tablet 3 times a day plus conventional therapy. The second group (n = 26) received the same therapy but a placebo tablet instead of silymarin. The patients were visited monthly and glycosylated hemoglobin (HbA(1)c), fasting blood glucose (FBS), insulin, total cholesterol, LDL and HDL, triglyceride, SGOT and SGPT levels were determined at the beginning and the end of the study. The results showed a significant decrease in HbA(1)c, FBS, total cholesterol, LDL, triglyceride SGOT and SGPT levels in silymarin treated patients compared with placebo as well as with values at the beginning of the study in each group. In conclusion, silymarin treatment in type II diabetic patients for 4 months has a beneficial effect on improving the glycemic profile.

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Publishing Authors By Initials

HF Huseini,B Larijani,R Heshmat,H Fakhrzadeh,B Radjabipour,T Toliat,M Raza,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Phytotherapy research : PTR

VOLUME: 20

Page Numbers: 1036-9

Journal Abbreviation:

ISSN: 0951-418X

DAY: 28

MONTH: Dec

YEAR: 2006

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8904486

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.

AFFILIATION: Department of Pharmacology, Institute of Medicinal Plants, ACECR Tehran, Iran. huseini_fallah@yahoo.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Phytother Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The efficacy of Silybum marianum L Gaertn silymarin in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial Related Publications

• 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis.
• A child with acute appendicitis.
• An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
• Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin.
• Benign fibrous histiocytoma of the rib.
• Comment on: Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists: reply.
• Comparison of two methods (precipitation manual and fully automated enzymatic) for the analysis of HDL and LDL cholesterol.
• Computer audiogram.
• Current treatment options: impact of cytogenetics on the course of myelodysplasia.
• Disorders of sex development (DSDs), their presentation and management in different cultures.
• Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
• Facilitating treatment of anxiety disorders in patients with comorbid medical illness.
• Immunomodulatory drugs in myelodysplastic syndromes.
• In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.
• In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.
• Interferon alpha 2a in patients of chronic hepatitis C.
• Localized lesions in secondary syphilis.
• Myocardial revascularization.
• Power Doppler sonography of breast cancer: does vascularity correlate with node status or lymphatic vascular invasion?
• Re: Obtaining previous mammograms for comparison.
• Silent myocardial ischemia.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• The assessment of risk factors for postoperative nausea and vomiting.
• The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
• The role of family configuration in early childhood intellectual development in the context of an extended family system in Pakistan.
• Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making.